SCHEMBL24176802

SCHEMBL24176802

CC(C)Cc1ccc(F)cc1C(F)F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 2/20 0.35
GABRB2 P47870 2/20 0.35
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
SLC6A2 P23975 2/20 0.33
SLC6A4 P31645 2/20 0.33
SLC6A3 Q01959 2/20 0.33
FFAR1 O14842 1/20 0.33
FFAR4 Q5NUL3 1/20 0.33
CTSS P25774 1/20 0.33
CTSK P43235 1/20 0.33
IDO1 P14902 2/20 0.32
AGXT P21549 2/20 0.32
MEN1 O00255 1/20 0.32
LMNA P02545 1/20 0.32
HPGD P15428 1/20 0.32
CRHBP P24387 1/20 0.32
HTT P42858 1/20 0.32
KMT2A Q03164 1/20 0.32
CRHR2 Q13324 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14485293 0.86 GABRA1 (0.36) GABRA1GABRB2HTR2AHTR2CSLC6A2
SCHEMBL20831728 0.80 IDO1 (0.34) HTR2AHTR2CFFAR1FFAR4IDO1
SCHEMBL21725483 0.80 FFAR1 (0.37) FFAR1FFAR4IDO1AGXTLMNA
SCHEMBL8227727 0.78 IDO1 (0.48) GABRA1GABRB2HTR2AHTR2CSLC6A2
SCHEMBL12169264 0.78 GABRA1 (0.39) GABRA1GABRB2HTR2AHTR2CSLC6A2
SCHEMBL20817936 0.76 IDO1 (0.34) FFAR1FFAR4IDO1AGXTSMN1; SMN2
SCHEMBL20818008 0.76 MPO (0.42) HTR2ASLC6A4FFAR1FFAR4IDO1
SCHEMBL30476381 0.76 MPO (0.42) HTR2ASLC6A4FFAR1FFAR4IDO1
SCHEMBL20817922 0.76 FFAR4 (0.37) FFAR1FFAR4IDO1AGXTSMN1; SMN2
SCHEMBL21503461 0.76 GABRA1 (0.50) GABRA1GABRB2HTR2AHTR2CTRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11713316-B2 Substituted naphthyridinone compounds useful as T cell activators BRISTOL-MYERS SQUIBB COMPANY (US) 2023-08-01 US disclosed
EP-4174069-A1 HETEROCYCLIC COMPOUND AND USE THEREOF Wuhan LL Science and Technology Development Co., Ltd. (CN) 2023-05-03 EP disclosed
WO-2022001767-A1 HETEROCYCLIC COMPOUND AND USE THEREOF 武汉朗来科技发展有限公司 2022-01-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11713316-B2 Substituted naphthyridinone compounds useful as T cell activators DGKZ, DGKA, DGKG GABRA1 3876/4885GABRB2 4385/4885HTR2A 4522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.